Abstract:Despite recent clinical progress in peptide-based dual inhibitors of MDM2/4, small-molecule ones with robust antitumor activities remain challenging. To tackle this issue, 31 (YL93) was structure-based designed and synthesized, which had MDM2/4 binding Ki values of 1.1 and 642 nM, respectively. In three MDM4-overexpressing cancer cell lines harboring wild-type p53, 31 shows improved cell growth inhibition activities compared to RG7388, an MDM2-selective inhibitor in late-stage clinical trials. Mechanistic studies show that 31 increased cellular protein levels of p53 and p21 and upregulated the expression of p53-targeted genes in RKO cells with MDM4 amplification. In addition, 31 induced cell-cycle arrest and apoptosis in western blot and flow cytometry assays. Taken together, dual inhibition of MDM2/4 by 31 elicited stronger antitumor activities in vitro compared to selective MDM2 inhibitors in wild-type p53 and MDM4-overexpressing cancer cells.The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acs.jmedchem.2c00095.qPCR analysis of TP53 and MDM4 genes in RKO cells in the presence of YL93 for 24 h (Figure S1); flow cytometry figures of cell-cycle arrest upon treatment of RG7388 and Nutlin-3a for 24 h (Figure S2); flow cytometry figures of apoptosis induction upon treatment of Nutlin-3a for 48 h (Figure S3); efficacy studies in the RKO xenograft model in nude mice (Figure S4); western blot analysis of 31 (YL93) and RG7388 in HCT-116 cells (Figure S5); cell growth inhibition of YL93, YM129, RG7388, and Nutlin-3 in HEK-293 cells (Figure S6); pharmacokinetic parameters of YL93 in ICR mice (Table S1); and X-ray crystallography data of 57 (Table S2) (PDF)Molecular formula string (CSV)This article has not yet been cited by other publications.

Synthesis and biological evaluation of 4-imidazolidinone–containing compounds as potent inhibitors of the MDM2/p53 interaction

Small Molecule Inhibitors of the P53-Mdm2

Synthesis and biological evaluation of thio-benzodiazepines as novel small molecule inhibitors of the p53-MDM2 protein-protein interaction.

Discovery, Synthesis, and Biological Evaluation of Orally Active Pyrrolidone Derivatives As Novel Inhibitors of P53-Mdm2 Protein-Protein Interaction.

Design, synthesis and in vitro and in vivo antitumour activity of 3-benzylideneindolin-2-one derivatives, a novel class of small-molecule inhibitors of the MDM2-p53 interaction.

Pharmacological Activation of the P53 Pathway by a New Compound CYZ2017 Exerts Anti-Tumor Effects

Design, synthesis and biological evaluation of novel 3,4,5-trisubstituted aminothiophenes as inhibitors of p53-MDM2 interaction. Part 2.

Synthesis and Biological Evaluation of Novel Synthetic Indolone Derivatives as Anti-Tumor Agents Targeting p53-MDM2 and p53-MDMX

Design, synthesis and biological evaluation of novel pyrrolidone-based derivatives as potent p53-MDM2 inhibitors

Molecular Modeling and Molecular Dynamics Simulation Studies on Pyrrolopyrimidine-Based Α-Helix Mimetic As Dual Inhibitors of MDM2 and MDMX

Small Molecule Agents Targeting the P53-Mdm2 Pathway for Cancer Therapy

Identification of Novel Inhibitors of P53–mdm2 Interaction Facilitated by Pharmacophore-Based Virtual Screening Combining Molecular Docking Strategy

Targeting p53–MDM2 interaction by small-molecule inhibitors: learning from MDM2 inhibitors in clinical trials

Pharmacologic Activation of P53 by Small-Molecule MDM2 Antagonists.

Computational Analysis of Spiro-Oxindole Inhibitors of the MDM2-p53 Interaction: Insights and Selection of Novel Inhibitors.

Design, synthesis and biological evaluation of sulfamide and triazole benzodiazepines as novel p53-MDM2 inhibitors.

Structure-Based Discovery of MDM2/4 Dual Inhibitors that Exert Antitumor Activities against MDM4-Overexpressing Cancer Cells

Synthesis and Biological Evaluation of Novel Pyrimido[4,5-B]quinoline-2,4- Dione Derivatives As MDM2 Ubiquitin Ligase Inhibitors.

Small-Molecule Inhibitors of the MDM2-p53 Protein-Protein Interaction to Reactivate p53 Function: A Novel Approach for Cancer Therapy

The initial evaluation of non-peptidic small-molecule HDM2 inhibitors based on p53-HDM2 complex structure.

Design, Synthesis and Biological Evaluation of Novel Antitumor Spirotetrahydrothiopyran-Oxindole Derivatives As Potent P53-Mdm2 Inhibitors